Niclosamide


CAS No. : 50-65-7

Niclosamide,50-65-7
Product Details
Cat No:A000928
Synonyms:50-65-7; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Niclocide; Bayluscid; Phenasal
Molecular Formula:C₁₃H₈Cl₂N₂O₄
Molecular Weight:327.12
Target:STAT
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Cat No:A000928
Cas No:50-65-7
Product-Name:Niclosamide
MDL No:MFCD00057597
InChI:InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)
InChIKey:RJMUSRYZPJIFPJ-UHFFFAOYSA-N
SMILES:C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O
Niclosamide is an oral antihelminthic drug, which has been used to treat tapeworm infection for about 50 years. Niclosamide is also used as a molluscicide for water treatment in schistosomiasis control programs. Recently, several groups have independently discovered that niclosamide is also active against cancer cells. Evidence supports that niclosamide targets multiple signaling pathways (NF-κB, Wnt/β-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells. Given its potential antitumor activity, clinical trials for niclosamide and its derivatives are warranted for cancer treatment.
1: Naqvi S, Mohiyuddin S, Gopinath P. Niclosamide loaded biodegradable chitosan nanocargoes: an in vitro study for potential application in cancer therapy. R Soc Open Sci. 2017 Nov 8;4(11):170611. doi: 10.1098/rsos.170611. eCollection 2017 Nov. PubMed PMID: 29291056; PubMed Central PMCID: PMC5717630.
2: Zuo Y, Yang D, Yu Y, Xiang M, Li H, Yang J, Li J, Jiang D, Zhou H, Xu Z, Yu Z. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc. Mol Med Rep. 2017 Dec 18. doi: 10.3892/mmr.2017.8301. [Epub ahead of print] PubMed PMID: 29257330.
3: Li X, Yang Z, Han Z, Wen Y, Ma Z, Wang Y. Niclosamide acts as a new inhibitor of vasculogenic mimicry in oral cancer through upregulation of miR-124 and downregulation of STAT3. Oncol Rep. 2018 Feb;39(2):827-833. doi: 10.3892/or.2017.6146. Epub 2017 Dec 11. PubMed PMID: 29251334.
4: Barini E, Miccoli A, Tinarelli F, Mulholand K, Kadri H, Khanim F, Stojanovski L, Read KD, Burness K, Blow JJ, Mehellou Y, Muqit M. The Anthelmintic Drug Niclosamide and its Analogues Activate the Parkinson/'s Disease Associated Protein Kinase PINK1. Chembiochem. 2017 Dec 10. doi: 10.1002/cbic.201700500. [Epub ahead of print] PubMed PMID: 29226533.
5: Xie Y, Yao Y. Octenylsuccinate hydroxypropyl phytoglycogen enhances the solubility and in-vitro antitumor efficacy of niclosamide. Int J Pharm. 2018 Jan 15;535(1-2):157-163. doi: 10.1016/j.ijpharm.2017.11.004. Epub 2017 Nov 4. PubMed PMID: 29113805.
6: Rehman MU, Khan MA, Khan WS, Shafique M, Khan M. Fabrication of Niclosamide loaded solid lipid nanoparticles: in vitro characterization and comparative in vivo evaluation. Artif Cells Nanomed Biotechnol. 2017 Nov 7:1-9. doi: 10.1080/21691401.2017.1396996. [Epub ahead of print] PubMed PMID: 29113501.
7: Li X, Ding R, Han Z, Ma Z, Wang Y. Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. Biomed Pharmacother. 2017 Dec;96:434-442. doi: 10.1016/j.biopha.2017.09.149. Epub 2017 Oct 12. PubMed PMID: 29031202.
8: Arkhipov IA, Sadov KM, Limova YV, Sadova AK, Varlamova AI, Khalikov SS, Dushkin AV, Chistyachenko YS. The efficacy of the supramolecular complexes of niclosamide obtained by mechanochemical technology and targeted delivery against cestode infection of animals. Vet Parasitol. 2017 Nov 15;246:25-29. doi: 10.1016/j.vetpar.2017.08.019. Epub 2017 Sep 1. PubMed PMID: 28969776.
9: Cheng B, Morales LD, Zhang Y, Mito S, Tsin A. Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line. PLoS One. 2017 Sep 6;12(9):e0184324. doi: 10.1371/journal.pone.0184324. eCollection 2017. PubMed PMID: 28877265; PubMed Central PMCID: PMC5587337.
10: Li Z, Li Q, Wang G, Huang Y, Mao X, Zhang Y, Wang X. Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma. Am J Transl Res. 2017 Aug 15;9(8):3776-3786. eCollection 2017. PubMed PMID: 28861168; PubMed Central PMCID: PMC5575191.
Related Products
  • CAS No. :285986-31-4
    Product Name:

    Stat5 Inhibitor

    Cat No: I011805 View details
  • CAS No. :501919-59-1
    Product Name:

    Stat3 Inhibitor I, S3I-201

    Cat No: I003766 View details
  • CAS No. :35825-57-1
    Product Name:

    Cryptotanshinone

    Cat No: I003313 View details
  • CAS No. :775351-88-7
    Product Name:

    Corylifol A

    Cat No: I004856 View details